Harmony Biosciences Holdings (HRMY) Receivables - Net (2019 - 2025)
Harmony Biosciences Holdings (HRMY) has disclosed Receivables - Net for 7 consecutive years, with $96.8 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 16.56% to $96.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.8 million through Dec 2025, up 16.56% year-over-year, with the annual reading at $96.8 million for FY2025, 16.56% up from the prior year.
- Receivables - Net hit $96.8 million in Q4 2025 for Harmony Biosciences Holdings, down from $100.7 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $106.0 million in Q1 2025 to a low of $23.6 million in Q1 2021.
- Historically, Receivables - Net has averaged $65.1 million across 5 years, with a median of $65.5 million in 2023.
- Biggest five-year swings in Receivables - Net: skyrocketed 103.39% in 2021 and later increased 11.81% in 2025.
- Year by year, Receivables - Net stood at $34.8 million in 2021, then soared by 57.1% to $54.7 million in 2022, then surged by 35.44% to $74.1 million in 2023, then grew by 11.99% to $83.0 million in 2024, then rose by 16.56% to $96.8 million in 2025.
- Business Quant data shows Receivables - Net for HRMY at $96.8 million in Q4 2025, $100.7 million in Q3 2025, and $93.0 million in Q2 2025.